NCT04118127View on ClinicalTrials.gov

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

February 16, 2021

Study Completion Date

March 3, 2021

Conditions
Schizophrenia
Interventions
DRUG

2mg conventional tablet, once-weekly tablets

In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.

Trial Locations (1)

Unknown

Sankeikai Nishigahara Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY